Skip to main content
Erschienen in: International Cancer Conference Journal 4/2017

01.08.2017 | Case report

Complete resection of a huge pancreatic undifferentiated carcinoma with osteoclast-like giant cells

verfasst von: Tomohiro Yazawa, Akira Watanabe, Kenichiro Araki, Atsuki Segawa, Keitaro Hirai, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Norihiro Ishii, Kouki Hoshino, Hiroyuki Kuwano, Ken Shirabe

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells (PUC-OGC) is a rare neoplasm. We report a case of rapidly advancing PUC-OGC. A 54-year-old man had elevated tumor marker levels. Abdominal computed tomography showed a cystic mass in the body and tail of the pancreas, which infiltrated adjacent organs. The tumor exhibited rapid growth (doubling time: 39 days) but no metastases. We diagnosed PUC-OGC clinically and excised the pancreatic body and tail along with the spleen, left kidney, adrenal gland, and transverse colon. Pathological diagnosis showed histology consistent with PUC-OGC and a negative margin without nodal involvement despite the tumor being 28 cm in maximum diameter and having invaded the left kidney. The patient survived a year with a recurrence of liver metastasis after the initial surgery due to the partial hepatectomy and chemotherapy. Complete resection might be a good strategy to cure PUC-OGC in this case.
Literatur
1.
Zurück zum Zitat Chen J, Baithun SI (1985) Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 146:17–29CrossRefPubMed Chen J, Baithun SI (1985) Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 146:17–29CrossRefPubMed
2.
Zurück zum Zitat Morohoshi T, Held G, Klöppel G (1983) Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 7:645–661CrossRefPubMed Morohoshi T, Held G, Klöppel G (1983) Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 7:645–661CrossRefPubMed
4.
Zurück zum Zitat Rosai J (1968) Carcinoma of pancreas simulating giant cell tumor of bone. Electron-microscopic evidence of its acinar cell origin. Cancer 22:333–344CrossRefPubMed Rosai J (1968) Carcinoma of pancreas simulating giant cell tumor of bone. Electron-microscopic evidence of its acinar cell origin. Cancer 22:333–344CrossRefPubMed
5.
Zurück zum Zitat Shiozawa M, Imada T, Ishiwa N et al (2002) Osteoclast-like giant cell tumor of the pancreas. Int J Clin Oncol 7:376–380CrossRefPubMed Shiozawa M, Imada T, Ishiwa N et al (2002) Osteoclast-like giant cell tumor of the pancreas. Int J Clin Oncol 7:376–380CrossRefPubMed
7.
Zurück zum Zitat Bergmann F, Esposito J, Michalski CW et al (2007) Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am J Surg Pathol 31:1919–1925CrossRefPubMed Bergmann F, Esposito J, Michalski CW et al (2007) Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am J Surg Pathol 31:1919–1925CrossRefPubMed
8.
Zurück zum Zitat Strobel O, Hartwig W, Bergmann F et al (2011) Anaplastic pancreatic cancer: presentation, surgical management, and outcome. Surgery 149:200–208CrossRefPubMed Strobel O, Hartwig W, Bergmann F et al (2011) Anaplastic pancreatic cancer: presentation, surgical management, and outcome. Surgery 149:200–208CrossRefPubMed
9.
Zurück zum Zitat Clark CJ, Graham RP, Arun JS et al (2012) Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg 215:627–634CrossRefPubMed Clark CJ, Graham RP, Arun JS et al (2012) Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg 215:627–634CrossRefPubMed
10.
Zurück zum Zitat Singhal A, Shrago SS, Li SF et al (2010) Giant cell tumor of the pancreas: a pathological diagnosis with poor prognosis. Hepatobiliary Pancreat Dis Int 9:433–437PubMed Singhal A, Shrago SS, Li SF et al (2010) Giant cell tumor of the pancreas: a pathological diagnosis with poor prognosis. Hepatobiliary Pancreat Dis Int 9:433–437PubMed
11.
Zurück zum Zitat Kobayashi S, Nakano H, Ooike N et al (2014) Long-term survivor of a resected undifferentiated pancreatic carcinoma with osteoclast-like giant cells who underwent a second curative resection: a case report and review of literature. Oncol Lett 8:1499–1504PubMedPubMedCentral Kobayashi S, Nakano H, Ooike N et al (2014) Long-term survivor of a resected undifferentiated pancreatic carcinoma with osteoclast-like giant cells who underwent a second curative resection: a case report and review of literature. Oncol Lett 8:1499–1504PubMedPubMedCentral
12.
Zurück zum Zitat Gao HQ, Yang YM, Zhuang Y et al (2015) Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas. World J Gastroenterol 21:694–698CrossRefPubMedPubMedCentral Gao HQ, Yang YM, Zhuang Y et al (2015) Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas. World J Gastroenterol 21:694–698CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Klein WMl, Hruban RH, Klein-Szanto AJ et al (2002) Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15:441–447CrossRefPubMed Klein WMl, Hruban RH, Klein-Szanto AJ et al (2002) Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15:441–447CrossRefPubMed
14.
Zurück zum Zitat Yoshioka M, Uchinami H, Watanabe G et al (2012) Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombosis. Intern Med 51:2145–2150CrossRefPubMed Yoshioka M, Uchinami H, Watanabe G et al (2012) Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombosis. Intern Med 51:2145–2150CrossRefPubMed
15.
Zurück zum Zitat Matsuzawa G, Shirabe K, Gion T et al (2010) Surgically resected undifferentiated carcinoma with osteoclast-like giant cells of the periampullary region involving the orifice of the papilla of Vater: report of a case. Surg Today 40:376–379CrossRefPubMed Matsuzawa G, Shirabe K, Gion T et al (2010) Surgically resected undifferentiated carcinoma with osteoclast-like giant cells of the periampullary region involving the orifice of the papilla of Vater: report of a case. Surg Today 40:376–379CrossRefPubMed
17.
Zurück zum Zitat Drexler LJ, Mitre RJ, Madan E et al (1986) Pancreatic giant cell carcinoma of the osteoclastic type: response to 5-fluorouracil and radiation. Am J Gastroenterol 81:1093–1097PubMed Drexler LJ, Mitre RJ, Madan E et al (1986) Pancreatic giant cell carcinoma of the osteoclastic type: response to 5-fluorouracil and radiation. Am J Gastroenterol 81:1093–1097PubMed
18.
Zurück zum Zitat Moore JC, Bentz JS, Hilden K et al (2010) Osteoclastic and pleomorphic giant cell tumors of the pancreas: a review of clinical, endoscopic, and pathologic features. World J Gastrointest Endosc 2:15–19CrossRefPubMedPubMedCentral Moore JC, Bentz JS, Hilden K et al (2010) Osteoclastic and pleomorphic giant cell tumors of the pancreas: a review of clinical, endoscopic, and pathologic features. World J Gastrointest Endosc 2:15–19CrossRefPubMedPubMedCentral
Metadaten
Titel
Complete resection of a huge pancreatic undifferentiated carcinoma with osteoclast-like giant cells
verfasst von
Tomohiro Yazawa
Akira Watanabe
Kenichiro Araki
Atsuki Segawa
Keitaro Hirai
Norio Kubo
Takamichi Igarashi
Mariko Tsukagoshi
Norihiro Ishii
Kouki Hoshino
Hiroyuki Kuwano
Ken Shirabe
Publikationsdatum
01.08.2017
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0305-y

Weitere Artikel der Ausgabe 4/2017

International Cancer Conference Journal 4/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.